Research menu
Jump to menu

Publications:  Prof Maralyn Druce

White BE, Druce MR, Grozinsky-Glasberg S, Srirajaskanthan R, Gamper EM, Gray D, Mujica-Mota R, Ramage JK(2020). Health-related quality of life in neuroendocrine neoplasia: a critical review. Endocrine-related cancer vol. 27, (7) R267-R280.
Chowdhury TA, Khan H, Druce MR, Drake WM, Rajakariar R, Thuraisingham R, Dobbie H, Parvanta L et al.(2019). Flipped learning: Turning medical education upside down. Future Healthc J vol. 6, (3) 192-195.
Lim ES, Shah SG, Waterhouse M, Akker S, Drake W, Plowman N, Berney DM, Richards P et al.(2019). Impact of thyroiditis on 131I uptake during ablative therapy for differentiated thyroid cancer. Endocrine Connections vol. 8, (5) 454-461.
Castinetti F, Waguespack SG, Machens A, Uchino S, Hasse-Lazar K, Sanso G, Else T, Dvorakova S et al.(2019). Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study. The Lancet Diabetes and Endocrinology vol. 7, (3) 213-220.
Hu MI, Elisei R, Dedecjus M, Popovtzer A, Druce M, Kapiteijn E, Pacini F, Locati L et al.(2019). Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer. Endocrine-Related Cancer vol. 26, (2) 241-250.
Lim ES, Shah SG, Waterhouse M, Akker S, Drake W, Plowman N, Berney DM, Richards P et al.(2019). Impact of thyroiditis on<sup>131</sup>i uptake during ablative therapy for differentiated thyroid cancer. Endocrine Connections vol. 8, (5) 571-578.
Ho W, Druce M(2018). Quality of life in patients with adrenal disease: A systematic review. Clinical Endocrinology vol. 89, (2) 119-128.
Ruiz-Babot G, Balyura M, Hadjidemetriou I, Ajodha SJ, Taylor DR, Ghataore L, Taylor NF, Schubert U et al.(2018). Modeling Congenital Adrenal Hyperplasia and Testing Interventions for Adrenal Insufficiency Using Donor-Specific Reprogrammed Cells. Cell Reports vol. 22, (5) 1236-1249.
O¿Shea T, Druce M(2017). When should genetic testing be performed in patients with neuroendocrine tumours?. Reviews in Endocrine and Metabolic Disorders vol. 18, (4) 499-515.
Druce M, Howden S(2017). New perspectives on health professions students’ e-learning: Looking through the lens of the “visitor and resident” model. Medical Teacher vol. 39, (7) 704-709.
Sze CWC, O'Toole SM, Tirador RK, Akker SA, Matson M, Perry L, Druce MR, Dekkers T et al.(2017). Adrenal Vein Catecholamine Levels and Ratios: Reference Intervals Derived from Patients with Primary Aldosteronism. Hormone and Metabolic Research vol. 49, (6) 418-423.
Hannon MJ, Sze WC, Carpenter R, Parvanta L, Matson M, Sahdev A, Druce MR, Berney DM et al.(2017). Clinical outcomes following unilateral adrenalectomy in patients with primary aldosteronism. QJM vol. 110, (5) 277-281.
Chowdhury TA, Druce MR, Drake WM, Rajakariar R, Thuraisingham R, Dobbie H, Parvanta L, Chinegwundoh F et al. (2017). An evaluation of "flipped learning" in undergraduate teaching in endocrinology and diabetes. DIABETIC MEDICINE. vol. 34, 109-109.
Tufton N, Gunganah K, Hussain S, Druce M, Carpenter R, Ashby M, Drake WM, Akker SA (2017). Alpha blockade—not to be underdone. vol. 86, is. 2, pp. 306-308.
Tufton N, Shapiro L, Srirangalingam U, Richards P, Sahdev A, Kumar AV, McAndrew L, Martin L et al.(2017). Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers. Clinical Endocrinology vol. 86, (2) 286-296.
Srirangalingam U, Banerjee A, Patki P, Peters J, George E, Chew SL, Kumar VKA, Korbonits M et al.(2017). Succinate Dehydrogenase B (SDHB)-Associated Bladder Paragangliomas. Clinical Genitourinary Cancer vol. 15, (1) e131-e136.
Druce MR, Hickey A, Warrens AN, Westwood OMR(2016). Medical Students Raising Concerns. Journal of Patient Safety
Qureshi SA, Burch N, Druce M, Hattersley JG, Khan S, Gopalakrishnan K, Darby C, Wong JLH et al.(2016). Screening for malnutrition in patients with gastro-entero-pancreatic neuroendocrine tumours: a cross-sectional study. BMJ Open vol. 6, (5) e010765-e010765.
Marques P, Van Huellen H, Fitzpatrick A, Druce M(2016). Late endocrine effects of cancer and cancer therapies in survivors of childhood malignancies. Minerva Endocrinologica vol. 41, (1) 78-104.
Soh LM, Druce M, Grossman AB, Differ A-M, Rajput L, Bitner-Glindzicz M, Korbonits M(2015). Evaluation of genotype-phenotype relationships in patients referred for endocrine assessment in suspected Pendred syndrome. Eur J Endocrinol vol. 172, (2) 217-226.
Dénes J, Swords F, Rattenberry E, Stals K, Owens M, Cranston T, Xekouki P, Moran L et al.(2015). Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: Results from a large patient cohort. Journal of Clinical Endocrinology and Metabolism vol. 100, (3) E531-E541.
Roff S, Druce M, Livingston K, Roberts CM, Stephenson A(2015). Mapping norms of academic integrity as an aid to proactive regulation. Journal of Medical Licensure and Discipline vol. 101, (3) 24-31.
Yang L, Mann K, Winceslaus J, Khan R, Berney D, Akker S, Waterhouse M, Drake W et al. (2014). Characteristics of 'foregut' carcinoid tumours occurring in multiple endocrine neoplasia type 1 (MEN1). WIENER KLINISCHE WOCHENSCHRIFT. vol. 126, S147-S147.
Bhattacharya S, Vyas S, Drake WM, Druce M (2014). Localisation and surgical resection of pancreatic insulinomas. WIENER KLINISCHE WOCHENSCHRIFT. vol. 126, S149-S149.
Schoenmakers N, Moran C, Campi I, Agostini M, Bacon O, Rajanayagam O, Schwabe J, Bradbury S et al.(2014). A novel albumin gene mutation (R222I) in familial dysalbuminemic hyperthyroxinemia. J Clin Endocrinol Metab vol. 99, (7) E1381-E1386.
Sze WCC, Soh LM, Lau JH, Reznek R, Sahdev A, Matson M, Riddoch F, Carpenter R et al.(2014). Diagnosing unilateral primary aldosteronism - comparison of a clinical prediction score, computed tomography and adrenal venous sampling. Clin Endocrinol (Oxf) vol. 81, (1) 25-30.
Banerjee A, Srirangalingam U, George E, Berney D, Patki P, Peters J, Druce M, Waterhouse M et al. (2014). Clinical Manifestations of SDH Associated Bladder Paragangliomas. ENDOCRINE REVIEWS. vol. 35,
Soh LM, Druce M, Grossman AB, Differ A-M, Rajput L, Bitner-Glindzicz M, Korbonits M (2014). Strong Genotype-Phenotype Correlation in Pendred Syndrome Allows Reduced Endocrine Follow-up in Suitable Patients. ENDOCRINE REVIEWS. vol. 35,
Sen Gupta P, Grozinsky-Glasberg S, Drake WM, Akker SA, Perry L, Grossman AB, Druce MR(2014). Are serotonin metabolite levels related to bone mineral density in patients with neuroendocrine tumours?. Clin Endocrinol (Oxf) vol. 80, (2) 246-252.
Solomou S, Khan R, Propper D, Berney D, Druce M(2014). A case of insulin and ACTH co-secretion by a neuroendocrine tumour. Endocrinol Diabetes Metab Case Rep vol. 2014,
Druce M(2014). Addressing quality in endocrine care. Clinical Endocrinology
Nadarasa K, Bailey M, Chahal H, Raja O, Bhat R, Gayle C, Grossman AB, Druce MR(2014). The use of cinacalcet in pregnancy to treat a complex case of parathyroid carcinoma. Endocrinol Diabetes Metab Case Rep vol. 2014,
Sze WCC, Grossman AB, Goddard I, Amendra D, Shieh SCC, Plowman PN, Drake WM, Akker SA et al.(2013). Sequelae and survivorship in patients treated with (131)I-MIBG therapy. Br J Cancer vol. 109, (3) 565-572.
Martins RG, Agrawal R, Berney DM, Reznek R, Matson M, Grossman AB, Druce MR(2012). Differential diagnosis of adrenocorticotropic hormone-independent Cushing syndrome: role of adrenal venous sampling. Endocr Pract vol. 18, (6) e153-e157.
Druce M, Chung T-T, Grozinsky-Glasberg S, Gross DJ, Grossman AB(2012). Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma. Clin Endocrinol (Oxf) vol. 77, (1) 154-155.
Druce MR, Walker D, Maher KT, Dodzo K, Perry L, Ball S, Peaston R, Chew SL et al.(2011). The effect of exogenous glucocorticoids on plasma catecholamines and metanephrines in patients without phaeochromocytomas. Horm Metab Res vol. 43, (4) 292-295.
Den Gupta P, Grozinsky-Glasberg S, Shimon I, Drake W, Akker S, Chew S, Grossman A, Druce M (2011). Evaluation of the Association between Serotonin and Bone Mineral Density in Patients with Neuroendocrine Tumors. NEUROENDOCRINOLOGY. vol. 94, 23-23.
Druce MR, Muthuppalaniappan VM, O'Leary B, Chew SL, Drake WM, Monson JP, Akker SA, Besser M et al.(2010). Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol vol. 162, (5) 971-978.
Druce MR, Akker SA, Chew SL, Drake WM, Grossman AB(2010). Morbidity in patients on long-term steroid replacement therapy. Clin Endocrinol (Oxf) vol. 72, (4) 564-566.
Druce MR, Bharwani N, Akker SA, Drake WM, Rockall A, Grossman AB(2010). Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine ('carcinoid') tumours of the small bowel. QJM vol. 103, (3) 177-185.
Liu YL, Ford HE, Druce MR, Minnion JS, Field BC, Shillito JC, Baxter J, Murphy KG et al.(2010). Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. International Journal of Obesity vol. 34, 1715-1725.
Druce MR, Lewington V, Grossman AB(2010). Targeted radionuclide therapy for neuroendocrine tumours: principles and application. Neuroendocrinology vol. 91, (1) 1-15.
Coelho C, Druce MR, Grossman AB(2009). Diagnosis of insulinoma in a patient with hypoglycemia without obvious hyperinsulinemia. NAT REV ENDOCRINOL vol. 5, (11) 628-631.
Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB(2009). Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res vol. 41, (9) 697-702.
Druce M, Rockall A, Grossman AB(2009). Fibrosis and carcinoid syndrome: from causation to future therapy. Nat Rev Endocrinol vol. 5, (5) 276-283.
Druce MR, Minnion JS, Field BC, Patel SR, Shillito JC, Tilby M, Beale KE, Murphy KG et al.(2009). Investigation of structure-activity relationships of Oxyntomodulin (Oxm) using Oxm analogues. Endocrinology vol. 150, (4) 1712-1722.
Druce M, Goldstone AP, Tan TMM, Meeran K(2008). The pursuit of beauty. LANCET vol. 371, (9612) 596-596.
Chaudhri OB, Parkinson JRC, Kuo YT, Druce MR, Herlihy AH, Bell JD, Dhillo WS, Stanley SA et al.(2006). Differential hypothalamic neuronal activation following peripheral injection of GLP-1 and oxyntomodulin in mice detected by manganese-enhanced magnetic resonance imaging. BIOCHEM BIOPH RES CO vol. 350, (2) 298-306.
Druce MR, Neary NM, Small CJ, Milton J, Monteiro M, Patterson M, Ghatei MA, Bloom SR(2006). Subcutaneous administration of ghrelin stimulates energy intake in healthy lean human volunteers. INT J OBESITY vol. 30, (2) 293-296.
Druce M, Bloom SR(2006). The regulation of appetite. ARCH DIS CHILD vol. 91, (2) 183-187.
Neary NM, Druce MR, Small CJ, Bloom SR(2006). Acylated ghrelin stimulates food intake in the fed and fasted states but desacylated ghrelin has no effect. GUT vol. 55, (1) 135-135.
Druce M, Ghatei M(2006). Oxyntomodulin. Current Opinion in Endocrinology and Diabetes vol. 13, (1) 49-55.
Druce MR, Bloom SR(2006). Oxyntomodulin : a novel potential treatment for obesity. Treat Endocrinol vol. 5, (5) 265-272.
Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, Filipsson K et al.(2005). Peptide YY3-36 and glucagon-like peptide-1(7-36) inhibit food intake additively. ENDOCRINOLOGY vol. 146, (12) 5120-5127.
Druce MR, Wren AM, Park AJ, Milton JE, Patterson M, Frost G, Ghatei MA, Small C et al.(2005). Ghrelin increases food intake in obese as well as lean subjects. Int J Obes (Lond) vol. 29, (9) 1130-1136.
Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA et al.(2004). Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J CLIN ENDOCR METAB vol. 89, (6) 2832-2836.
Druce MR, Small CJ, Bloom SR(2004). Minireview: Gut peptides regulating satiety. ENDOCRINOLOGY vol. 145, (6) 2660-2665.
Druce M, Bloom SR(2003). Central regulators of food intake. Curr Opin Clin Nutr Metab Care vol. 6, (4) 361-367.
Druce M, Morris VH, Stamp TCB(2002). A case report of myositis ossificans progressiva complicated by femoral nerve compression treated with radiotherapy. RHEUMATOLOGY vol. 41, (8) 947-948.
Druce M, Cohen IJ, Naor N, Shohat M(1995). Late diagnosis of Down syndrome due to incorrect cytogenetic diagnosis and extreme prematurity. Clin Genet vol. 48, (4) 192-194.
Return to top